TransMedics Group's trend of growing ROCE and increasing capital employed suggests profitable reinvestment opportunities, potentially leading to a multi-bagger performance. The stock's solid return to shareholders over the last three years indicates investor recognition of these changes.
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks. Here are some top stocks in the sector climbing on drug trial and earnings news: $Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap. $Ligand Pharmaceuticals (LGND.US)$gained 23%...
Insider selling over the past year, particularly in recent months, may indicate insiders believe shares are overpriced. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership shows alignment with shareholders, but past sales warrant caution.
TransMedics Group's significant top-line growth is undermined by its negative EBIT, liabilities outstripping cash and near-term receivables by $75m, and increased cash burn over the past year, constituting substantial risk.
Oppenheimer analysts hail TransMedics' recent quarter as 'blockbuster', emphasizing its long-term strategy to overcome short term challenges. The game-changing potential of the Organ Care System technology to reshape organ preservation and transport is also highlighted.
Positive interpretation of recent purchases at TransMedics Group amidst potential concerns over last year's sales. Insiders' stakes display alignment between management and smaller shareholders.
TransMedics股票讨论区
$BJ批发俱乐部(BJ.US)$ 虽然没有跌破止损,但在突破价位初期就出现大交易量派发,选择提前清仓;
$CAVA Group(CAVA.US)$ 持有大约1个月,目前每周图表相对10MA过度延伸,当前利润已经超过25%,选择卖出一半先锁定一些利润;
$NewAmsterdam Pharma(NAMS.US)$ 2个月左右的3T VCP 突破买入,价格很紧,交易量很干,持仓占比:3.79%;
$Vertex(VERX.US)$ 新高 回调后 紧密的 小基地突破买入,持仓占比:3.4%;
$TransMedics(TMDX.US)$ 在GOOG和AFRM 每周图表 围绕上升趋势的30MA附近的交易 工作不错的基调下,本周围绕每周图表仍然处于上升趋势的30MA买入了TMDX,它们的特点都是止损极小,但需要时间发挥作用,所以不会使用大的仓位,持仓占比:4.35%;
2024第一季度已经结束,3天的长周末即将来临,周末愉快🚴🏻
$Celsius Holdings(CELH.US)$ at $48 (this year) was the easiest money and people waited.
$Palantir(PLTR.US)$ at $14 was extremely undervalued and many waited
$Meta Platforms(META.US)$ was obvious to buy at $200 and everyone waited
$CrowdStrike(CRWD.US)$ was a clear buy at $150 and people waited
$TransMedics(TMDX.US)$ at $38 with a market cap of $1 Billion was a steal and nobody wanted to buy it.
Focus on the essentials: align...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
and why did this run up all on its own
暂无评论